Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Receivables (2021 - 2025)

Nurix Therapeutics (NRIX) has disclosed Receivables for 5 consecutive years, with $20.7 million as the latest value for Q2 2025.

  • Quarterly Receivables changed N/A to $20.7 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $20.7 million through May 2025, changed N/A year-over-year, with the annual reading at $5.0 million for FY2024, N/A changed from the prior year.
  • Receivables for Q2 2025 was $20.7 million at Nurix Therapeutics, up from $5.0 million in the prior quarter.
  • The five-year high for Receivables was $20.7 million in Q2 2025, with the low at $1.0 million in Q4 2022.
  • Average Receivables over 5 years is $7.4 million, with a median of $6.9 million recorded in 2021.
  • Peak annual rise in Receivables hit 85.51% in 2022, while the deepest fall reached 85.51% in 2022.
  • Over 5 years, Receivables stood at $6.9 million in 2021, then plummeted by 85.51% to $1.0 million in 2022, then surged by 700.0% to $8.0 million in 2023, then crashed by 37.5% to $5.0 million in 2024, then soared by 314.0% to $20.7 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $20.7 million, $5.0 million, and $8.0 million for Q2 2025, Q4 2024, and Q3 2023 respectively.